Comparative Pharmacology
Head-to-head clinical analysis: E E S versus ERYC 125.
Peer-Reviewed Evidence
Head-to-head clinical analysis: E E S versus ERYC 125.
E.E.S. vs ERYC 125
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Erythromycin (E.E.S.) binds to the 50S subunit of bacterial ribosomes, inhibiting peptide chain elongation and protein synthesis. It also exhibits prokinetic effects on the gastrointestinal tract via motilin receptor agonism.
Erythromycin binds to the 50S subunit of bacterial ribosomes, inhibiting protein synthesis by blocking translocation of peptidyl-tRNA. It also activates motilin receptors in the gastrointestinal tract, enhancing gastric motility.
250-500 mg every 6 hours orally or 15-20 mg/kg/day IV divided every 6 hours.
250 mg orally every 6 hours or 500 mg every 12 hours; maximum 4 g/day.
None Documented
None Documented
1.5-2 hours in adults with normal renal function; prolonged to 4-6 hours in patients with hepatic impairment; may be shorter in children.
1.5-2.0 hours in adults; prolonged in hepatic impairment (up to 5-6 hours) or neonates.
Primarily hepatic (biliary) excretion of unchanged drug and active metabolites; approximately 15% of an oral dose is excreted unchanged in urine. The remainder is eliminated via feces as unchanged drug and metabolites.
Primarily hepatic metabolism; ~2-5% excreted unchanged in urine, ~15-20% in bile/feces as active drug.
Category C
Category C
Macrolide Antibiotic
Macrolide Antibiotic